Fund moves
3.3%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
INO · NASDAQ · Pharmaceutical Preparations
Inovio Pharmaceuticals (INO) · oqro.io/stocks/INO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.76+0.05 (+2.92%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Inovio Pharmaceuticals was filed in the last 90 days. The latest on record was on Jan 13, 2020.
Since 2006, Inovio Pharmaceuticals insiders reported 65 open-market purchases and 141 sales on Forms 4 and 5, with purchases in 9 different years, most recently 2020.
No open-market sale by an insider of Inovio Pharmaceuticals (INO) was filed with the SEC in the last 90 days.
No trade in Inovio Pharmaceuticals (INO) was disclosed by a member of Congress in the last 12 months.
Inovio Pharmaceuticals's next results are expected on Mar 10, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+1.7% (+$0.03) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1.73 on Nov 20, 2025 to $1.76 on Nov 20, 2026 (+1.7%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Plymouth Meeting, Pa.
Last 12 months
+1.7%
Market value
$262M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 22.1M shares sold short (14.8% of shares outstanding), +3.7% vs the previous count, 1.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$65K
−70.0% vs the year before
Net income, fiscal 2025
−$84.9M
A loss for the year
Shares outstanding
187M
As of Nov 10, 2026
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
From a 13F filed Feb 14, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Nov 14, 2024 covering holdings at Sep 30, 2024 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Inovio Pharmaceuticals over the 12 months to Nov 18, 2026: 1 clinical trial.
Insiders of Inovio Pharmaceuticals reported 65 open-market purchases and 141 sales since 2006; purchases in 9 different years, most recently 2020.
| Year | Bought | Sold |
|---|---|---|
| 2023 | — | $25K3×3 trades |
| 2022 | — | $107K9×9 trades |
| 2021 | — | $5.4M28×28 trades |
| 2020 | $70K1×1 trade | $5.46M13×13 trades |
| 2019 | $60K2×2 trades | $5.88M8×8 trades |
| 2018 | — | $1.61M8×8 trades |
| 2017 | $133K1×1 trade | $1.03M3×3 trades |
| 2016 | $742K6×6 trades | $268K2×2 trades |
| 2015 | $142K3×3 trades | — |
| 2014 | $2.68M10×10 trades | — |
| 2013 | $596K12×12 trades | — |
| 2012 | $130K8×8 trades | $3.38M29×29 trades |
| 2011 | $363K22×22 trades | $6.77M36×36 trades |
| 2006 | — | $152K2×2 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
People read Inovio Pharmaceuticals's Wikipedia article about 12 times a day over the last week, close to the 12 on a usual day of the three months before.
May 15, 2026Busiest day: 150 views on Nov 2, 2026Nov 20, 2026
Views of the article Inovio Pharmaceuticals, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Revenue
$299K
Year earlier: $0
Free cash flow, last 12 months
−$74.4M
This quarter −$15.3M, a year earlier −$21.6M
Net debt
—
Debt —, cash $47M, at Sep 30, 2026
Net income, last 12 months
−$71.1M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 10, 2026.
Revenue and earnings history, 17 fiscal yearsEarnings dates and the stock's moves
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
We are a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. Our platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. We use proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body’s cells can download to produce specific proteins to target and fight disease. Our proprietary investigational CELLECTRA® devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors.
And 14 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 12, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in glioblastoma. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Last results
Nov 10, 2026
Within the 30 days after it, until Dec 10, 2026
Next results, expected
Mar 10, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
4%
1 of 23 insider purchases since 2014 came within 30 days after a results announcement
From Inovio Pharmaceuticals's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Inovio Pharmaceuticals's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Attention
Things to keep in mind
Records
Off-exchange trading: 57.9% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (10.2% on ATS, 47.7% with other brokers), close to its 26-week average of 57.2%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: MS POOL (ATS-4) (26.4%), INTELLIGENT CROSS LLC (10.2%), UBS ATS (8.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Latest annual report filed Mar 12, 2026, compared with the one filed Mar 18, 2025. Read the filing
VGXI Litigation: On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, collectively referred to as “VGXI”, alleging that VGXI materially breached the Company’s supply agreement. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys’ fees, interest, costs and other relief from VGXI.
Source: SEC EDGAR, Form 10-K filed Mar 12, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
FMR LLC
13G · passive · Amended · 15.4M shares · filed Nov 5, 2026
TANG CAPITAL MANAGEMENT, LLC
13G · passive · Crossed 5% · 18M shares · filed Nov 16, 2026
Highbridge Capital Management, LLC
13G · passive · Amended · 25.3M shares · filed Nov 16, 2026
ADAR1 Capital Management, LLC
13G · passive · Crossed 5% · 6.43M shares · filed Nov 16, 2026
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.